Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease
about
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responsesSodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's diseaseNovel High Content Screen Detects Compounds That Promote Neurite Regeneration from Cochlear Spiral Ganglion Neurons.Systemic simvastatin rescues retinal ganglion cells from optic nerve injury possibly through suppression of astroglial NF-κB activationAnkyrin repeat and BTB/POZ domain containing protein-2 inhibits the aggregation of alpha-synuclein: implications for Parkinson's diseaseNeuroprotection by a mitochondria-targeted drug in a Parkinson's disease modelSimvastatin treatment enhances NMDAR-mediated synaptic transmission by upregulating the surface distribution of the GluN2B subunit.Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease.Neuromelanin inhibits CXCL10 expression in human astroglial cells.Cholesterol in brain disease: sometimes determinant and frequently implicated.Molecular mechanisms underlying the effects of statins in the central nervous system.Pleiotropic effects of the HMG-CoA reductase inhibitorsCholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disordersProspects of statins in Parkinson diseaseIsoprenoids and related pharmacological interventions: potential application in Alzheimer's disease.HMG-CoA Reductase Inhibitors Bind to PPARα to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice.Attenuation of microglial RANTES by NEMO-binding domain peptide inhibits the infiltration of CD8(+) T cells in the nigra of hemiparkinsonian monkeyIntranasal Delivery of NEMO-Binding Domain Peptide Prevents Memory Loss in a Mouse Model of Alzheimer's Disease.Testing NF-κB-based therapy in hemiparkinsonian monkeysLiver X receptor β protects dopaminergic neurons in a mouse model of Parkinson diseaseSuppression of nuclear factor-κB activation and inflammation in microglia by physically modified saline.Statin adherence and the risk of Parkinson's disease: A population-based cohort study.Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: implications for neuronal self-defenseThe peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease.Neutralization of RANTES and Eotaxin Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson Disease.Castration induces Parkinson disease pathologies in young male mice via inducible nitric-oxide synthaseSimvastatin induces a central hypotensive effect via Ras-mediated signalling to cause eNOS up-regulation.Splice isoform and pharmacological studies reveal that sterol depletion relocalizes α-synuclein and enhances its toxicityConditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition.Parkinson's disease mouse models in translational research.Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors.Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in central nervous system disorders: a comprehensive review.Liver X receptors and cholesterol metabolism: role in ventral midbrain development and neurodegeneration.Sodium benzoate, a metabolite of cinnamon and a food additive, upregulates neuroprotective Parkinson disease protein DJ-1 in astrocytes and neurons.Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases.Harnessing the trophic and modulatory potential of statins in a dopaminergic cell line.Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.Molecular changes in the postmortem parkinsonian brain.
P2860
Q21560808-BADB4277-3038-4AC7-ABD8-3BA9B44A4BE9Q27301885-C434BD24-0572-40DD-9959-106FC7781C8BQ27307798-A92675F0-A818-4871-938D-974541D803E5Q27335272-DDA462F7-4F2B-4A71-B289-AAEA9316D3A3Q28505185-91F8109C-B2C3-43BF-AB3F-CD78FFAC5046Q33608424-BCF880F5-02E7-4962-A8C2-0628E6BA52E4Q34081527-698C5B3D-7A06-43B7-A02A-EDBA704C1AE3Q34205454-33CE26E3-4A12-45B4-960F-74843CDAA5D6Q34330789-0FDEF0FC-529D-4A8B-8F13-A022EEF6FBFFQ34621446-4E9FA908-D2D2-40C3-AE09-92ED618C9279Q34685463-1BF1B938-446E-4EF5-A6AD-E2DA75728AADQ34894749-3B7807D6-605C-4DCF-B2F0-83BE4C195C9EQ35087574-C327A617-5F25-4A97-BFB2-3B2D92E3C881Q35094028-7DF3861C-0497-4811-A2A5-4CEF983A0F13Q35634151-FF8E9D2B-C91E-467D-A50D-C5E9D8AB82AFQ35920862-16EF5F4C-0972-497F-B0FA-1D0817CA39CFQ35925076-9019E2E6-B249-4A13-9505-B01D2A0748B5Q36092100-89D8E9FF-C881-4831-868B-9100F19473E6Q36166141-7FD56AEA-9F73-43C2-8B0C-AB3EA78E9DD4Q36167615-9A383729-96D7-4B57-9349-739DC699546EQ36215873-B214D3C0-66F6-44BB-A656-42EC5A21ABB5Q36339785-884DDE69-5729-4EED-B3C9-3ADF27067BE5Q36369754-B21306A2-0D9C-4C1F-B076-34CD38F7EBCCQ36469000-0C8922A6-6623-4617-ACA8-73C16946FC1CQ37048463-9DE33282-83A5-4356-9C4E-55259AE3C6F9Q37098950-D08F92CC-6A90-4B82-9918-790C2CBB736CQ37175073-7BD4A8BE-B720-42D2-B8A4-7D0B959E99A1Q37237168-1238629B-06A7-4626-97F9-95E705644888Q37612718-2B14484B-8293-488B-B47E-DE02B6726431Q37715032-83DEA434-3B61-46DC-B11C-D54DD8E25C83Q37779428-64940F92-C3CD-4D89-9DD7-92E0E8B7D4AEQ37874160-11188D55-7BA8-44B9-A59B-69DEC0E1C6ACQ38009736-B0439568-1B85-459F-B9CF-58ABE6E316A6Q38020536-18D435CB-5057-42FD-A90E-E5512BBEDAC8Q38534041-49B14D06-9AE3-4D57-A961-7E8008565943Q38657861-54522924-4058-4466-B2AF-30AD67DF4473Q38728679-67F62D10-9AE4-45A2-8565-F9D0F3ADDBAFQ38809645-B2458CC3-4FB6-4DA7-BAA9-4B8912129D2CQ38859501-B2BC8FF9-9D20-4B1D-A6F4-E303B76DB719Q38887346-EB66832B-CD7A-4516-9B9B-04C8D3066748
P2860
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Simvastatin inhibits the activ ...... e model of Parkinson's disease
@ast
Simvastatin inhibits the activ ...... e model of Parkinson's disease
@en
Simvastatin inhibits the activ ...... e model of Parkinson's disease
@nl
type
label
Simvastatin inhibits the activ ...... e model of Parkinson's disease
@ast
Simvastatin inhibits the activ ...... e model of Parkinson's disease
@en
Simvastatin inhibits the activ ...... e model of Parkinson's disease
@nl
prefLabel
Simvastatin inhibits the activ ...... e model of Parkinson's disease
@ast
Simvastatin inhibits the activ ...... e model of Parkinson's disease
@en
Simvastatin inhibits the activ ...... e model of Parkinson's disease
@nl
P2093
P2860
P1476
Simvastatin inhibits the activ ...... e model of Parkinson's disease
@en
P2093
Anamitra Ghosh
Howard E Gendelman
Joanna Matras
Kalipada Pahan
Saurav Brahmachari
P2860
P304
P356
10.1523/JNEUROSCI.4144-09.2009
P407
P577
2009-10-28T00:00:00Z